Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00273338 · ClinicalTrials.gov registry record · Phase 3
DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])
A Phase 3 study, sponsored by Novacea.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
NCT00273338: Clinical Trial Phase 3 study, sponsored by Novacea.
NCT00273338 is a Phase 3 study that was terminated before completion, run by Novacea. The registered enrollment target is 1,200 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00273338, a Phase 3 study, was terminated before completion, sponsored by Novacea.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
Study Summary
The primary objective of this study is: * To evaluate the effect of DN-101 in combination with docetaxel (ASCENT regimen) on survival in metastatic androgen-independent prostate cancer The secondary objectives of this study are: * To determine the effect of the ASCENT regimen on the rate of thromboembolic events (blood clots) * To determine the effect of the ASCENT regimen on prevention of skeletal-related events (fractures) * A Separate sub-study will be conducted at selected study sites in North America to determine the population PK of DN-101.
Interventions
- DRUG docetaxel
- DRUG calcitriol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Why NCT00273338 stopped before completion
NCT00273338 is an interventional study that assigns participants to a tested intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% higher).
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00273338 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00273338 about?
NCT00273338 is a clinical study titled "DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])". The primary objective of this study is: * To evaluate the effect of DN-101 in combination with docetaxel (ASCENT regimen) on survival in metastatic androgen-independent prostate cancer The secondary objectives of this study are: * To determine the effect of the ASCENT regimen on the rate of throm...
What is the current status of trial NCT00273338?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2006-01. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00273338?
The interventions under investigation include: docetaxel (DRUG), calcitriol (DRUG).
Who is sponsoring clinical trial NCT00273338?
This trial is sponsored by Novacea, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00273338's enrollment target sits among peer trials
1,200 220th of 2000 higher than 1,773 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia